Skip to main content
European Commission logo print header

Unique approach to improving neurological function after stroke with SIN020

Project description

A repurposed drug for stroke treatment

Stroke affects nearly 1 million European citizens every year incurring costs of EUR 45 billion. Rehabilitation is the only available treatment to restore neurological function. The EU-funded SINSTRO project proposes to repurpose the SIN020 investigational drug that has previously been in clinical development for mental disorders to promote recovery of the post-stroke brain. SIN020 is an inhibitor of the glutamate receptor 5 (mGluR5) which is implicated in stroke-related neuroinflammation. Preliminary results in a mouse model of stroke have indicated that SIN020 helps reverse lost functions and has the potential to enter a clinical trial.

Objective

The aim of this project is to develop a business plan to guide clinical development and commercialisation of SIN020; a glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) to promote recovery of the injured stroke brain. Every year, 1 million people in Europe have a stroke and the healthcare and non-healthcare cost is estimated at EUR 45 billion. The only treatment option available for restoring neurological function in stroke patients is rehabilitation, which has limited effect. Since there is a 34% anticipated rise in the total number of stroke events between 2015 and 2035, there is a pressing need for a pharmacological intervention to help restore function after stroke. Sinntaxis is developing SIN020, a repurposed investigational drug that has previously been in clinical development for another indication and can therefore enter straight in to a Phase II clinical trial. In animal models, mGluR5 NAM has been shown to help reverse lost functions in animal models of stroke and we aim to translate this exciting preclinical data to clinically validated results. The current proposed Phase 1 project will facilitate in the development process and help define clinical and business strategies. SME Instrument funding will allow SIN020 to take a substantial step along the path of commercialisation.

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

æ

Coordinator

SINNTAXIS AB
Net EU contribution
€ 50 000,00
Address
Medicon village scheelevagen 2
223 81 Lund
Sweden

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Sydsverige Skåne län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 21 429,00